Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023

Alchemab’s Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer’s disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.

@media (min-width:1042px){ #menu-primary-nav .sub-menu{ transition:transform 233ms 610ms, opacity 89ms calc(233ms + 610ms - 89ms) linear; } } @media (max-width:1041px){ #primary-navigation .menu-primary-nav-container{ -webkit-transition: -webkit-transform .233s ease-out, opacity .233s linear; transition: transform .233s ease-out, opacity .233s linear; } }